Description

Simple

Clinical

Overview

Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Canrenoic acid
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abacavir
Canrenoic acid may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
Acarbose
Canrenoic acid may increase the excretion rate of Acarbose which could result in a lower serum level and potentially a reduction in efficacy.
Acebutolol
The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Canrenoic acid.
Aceclofenac
The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Canrenoic acid.
Acemetacin
The therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Acemetacin.
Acetaminophen
Canrenoic acid may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Acetyldigitoxin
Canrenoic acid may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level.
Acetyldigoxin
Canrenoic acid may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
Acetylsalicylic acid
Acetylsalicylic acid may decrease the excretion rate of Canrenoic acid which could result in a higher serum level.
Aclidinium
Canrenoic acid may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
Acrivastine
Canrenoic acid may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.
Acyclovir
Canrenoic acid may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.
Agmatine
The risk or severity of hyperkalemia can be increased when Agmatine is combined with Canrenoic acid.
Albutrepenonacog alfa
Canrenoic acid may increase the excretion rate of Albutrepenonacog alfa which could result in a lower serum level and potentially a reduction in efficacy.
Alclofenac
The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Alclofenac.
Aldesleukin
Canrenoic acid may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
Alfentanil
The therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Alfentanil.
Aliskiren
The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Aliskiren.
Alloin
The risk or severity of adverse effects can be increased when Canrenoic acid is combined with Alloin.
Allopurinol
Canrenoic acid may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.